PCM
AMRX icon

Penn Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Penn Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9M Buy
1,196,073
+194,122
+19% +$2.61M 1.15% 45
2025
Q4 		$12.7M Buy
+1,001,951
New +$11.5M 1.01% 56

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Penn Capital Management's AMRX Position: Q1 2026 in Review

Penn Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 19% in Q1 2026, buying an estimated $2.61M and bringing the position to 1,196,073 shares worth $14.9M. The position accounts for 1.15% of the portfolio, ranked #45.

Penn Capital Management first reported a position in AMRX in Q4 2025 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Penn Capital Management held 1,196,073 shares of Amneal Pharmaceuticals worth $14.9M as of Q1 2026.
  • Penn Capital Management bought 194,122 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.61M.
  • Amneal Pharmaceuticals made up 1.15% of Penn Capital Management's portfolio in Q1 2026, its #45 holding.
  • Penn Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.